Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

NCT ID: NCT02324803

Last Updated: 2014-12-24

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 86 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-31
• Study Completion Date: 2015-12-31

Brief Summary

assess the activity and toxicity of second-line treatment with pazopanib after failure of first-line sunitinib treatment in patients with clear cell mRCC; to investigate the potential association of DLL4, Notch1, VEGFA, PDGFRB, HIF-1α and HIF-2α with clinical response to pazopanib in mRCC patients.

Detailed Description

The primary end point was progression-free survival (PFS). Secondary end points were overall survival (OS), objective response rate (ORR) and safety. We assessed the tumor response according to the RECIST 1.1.

Efficacy was evaluated by computed tomography with contrast of the chest, abdomen, and pelvis. We performed tumor assessments with the use of imaging studies at baseline and every six weeks until the end of treatment. We also used such assessments to confirm a response (at least 4 weeks after initial documentation) and whenever disease progression was suspected. All imaging scans were evaluated by an independent imaging-review committee (IRC) blinded to study treatment. Patients who had inadequate data for study assessment was regarded as nonevaluable.

Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Safety was assessed by physical examination and laboratory tests. Electrocardiograms (ECGs) were performed at baseline and every six weeks until the end of treatment.

Conditions

Self Efficacy; Adverse Drug Event; Carcinoma, Renal Cell

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

pazopanib once daily

Patients received continuous treatment of 800 mg pazopanib once daily until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Dose reductions by 400 mg to a lowest dose of 200 mg daily were allowed on the basis of tolerability and according to protocol-defined guidelines.

Group Type: EXPERIMENTAL

pazopanib

Intervention Type: DRUG

continuous treatment of 800 mg pazopanib once daily until disease progression

Interventions

pazopanib

continuous treatment of 800 mg pazopanib once daily until disease progression

Intervention Type: DRUG

Other Intervention Names

Votrient

Eligibility Criteria

Inclusion Criteria

1. Written informed consent

2. Diagnosis of renal cell carcinoma with clear-cell component histology.

3. Locally advanced/metastatic renal cell carcinoma

4. Measurable lesion (RECIST 1.1) on physical exam or as CT/MRI

5. No prior systemic therapy for advanced/metastatic RCC

6. Karnofsky performance scale >=70

7. Age >=18 years

8. A female is eligible to enter and participate in this study if she is of: non-childbearing/agrees to use adequate contraception

9. A male with female partner of childbearing potential must have vasectomy/agree to use effective contraception from two weeks prior to administration of the 1st dose of study treatment for a period of time after the last dose of study treatment

10. Adequate organ function

11. Able to swallow and retain orally administered medication and must not have clinically significant GIT abnormalities that may alter absorption

12. The date of disease progression must be within six months of stopping sunitinib or during treatment with sunitinib

13. Measurable lesion at pazopanib baseline as per the RECIST 1.1 criteria

Exclusion Criteria

1. Pregnant/lactating

2. History of another malignancy (unless have been disease-free for 3 years)

3. History or clinical evidence of Central nervous system metastases (unless have previously-treated CNS metastases and who meet both of the following criteria: a) are asymptomatic and b) have no requirement for steroids or enzyme-inducing anticonvulsants in prior 6 month time interval.

4. Clinically significant gastrointestinal abnormalities including, but not limited to: malabsorption syndrome, major resection of the stomach or small bowel that could affect the absorption of study drug, active peptic ulcer disease, known intraluminal metastatic lesion/s with suspected bleeding, Inflammatory bowel disease, ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation, history of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess

5. Moderate to severe hepatic impairment (Child-Pugh Class C)

6. Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with patient's safety, obtaining informed consent or compliance to the study.

7. Subjects receiving chronic treatment with corticosteroids/other immunosuppressive agents

8. Subjects with a known history of HIV seropositivity

9. Subjects with active bleeding, bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin)

10. Presence of any severe or uncontrolled medical conditions/infection.

11. Currently receiving chemotherapy, immunotherapy or radiotherapy

12. Corrected QT interval (QTc) > 480 milliseconds

13. History of any one or more of the following cardiovascular conditions within the past 12 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery by-pass graft surgery, symptomatic peripheral vascular disease, Class III or IV congestive heart failure, as defined by the New York Heart Association

14. Poorly controlled hypertension (defined as systolic blood pressure of >=140mmHg or diastolic blood pressure of >=90mmHg).

15. History of cerebrovascular accident including transient ischemic attack, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months (unless recent DVT have been treated with therapeutic anti-coagulating agents for at least 6 weeks)

16. Major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.

17. Evidence of active bleeding or bleeding susceptibility.

18. Known endobronchial lesion and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrage

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Southern China Urology Cancer Consortium

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mian Xie

Role: PRINCIPAL_INVESTIGATOR

The First Affiliated Hospital of Guangzhou Medical University

Locations

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

Mian Xie

Role: CONTACT

Phone: 862083062956

Email: mianxie@gird.cn

Facility Contacts

Mian Xie

Role: primary

Other Identifiers

SUCC001

Identifier Type: -

Identifier Source: org_study_id